

Targeting PCOS-associated Insulin Resistance: Aerobic Exercise and Hypocaloric Diet without Medications could adjust the Hyperandrogenic milieu and help Induction of Ovulation in Infertile PCOS women

Mohamad F. Al-Sherbeny

Department of Obstetrics & Gynecology, Faculty of Medicine, Benha University, Egypt
Mahfarag61@yahoo.com

Abstract: Objectives: To evaluate the impact of weight reduction and exercise interventions on ovulatory function of infertile polycystic ovary syndrome (PCOS) women. Patients & Methods: 90 infertile PCOS women diagnosed depending on the Rotterdam criteria underwent anthropometric measurements and determination of body fat mass (FM), fat-free mass (FFM), and percent body fat (BF%) using dual-energy x-ray absorptiometry. Fasting blood glucose (FBG), plasma insulin (FPI) and serum testosterone (Test), sex hormone binding globulin (SHBG) were measured and free androgen index (FAI) was calculated. Insulin resistance (IR) was evaluated by homeostasis model assessment (HOMA) with HOMA-IR score >2 was considered insulin resistant (IR). All women performed 6-months weight-reduction dieting regimen in association with no exercise (Group A), aerobic exercise (Group B) or combined aerobic-resistance exercise (Group C). All measures were evaluated at 3 and 6-months but ovulation was monitored monthly. Results: At end of 6-months, all women showed significant change of anthropometric measures with significantly higher extent of change in groups B and C compared to group A. Also, IR was significantly modulated with significant reduction of HOMA-IR compared to pre-treatment levels; however, change was least in Group A and only 15 of 63 women were still IR. Serum testosterone and SHBG levels estimated at 6-m showed significant difference compared to baseline levels in groups B and C and all groups showed progressive decrease of FAI with significantly lower FAI level in group B compared to group A. Fifty-nine women got ovulation with ovulatory success rate of 65.6% with non-significant difference among studied groups. Conclusion: Weight reduction regimens associated with aerobic physical exercise intervention could induce weight loss and improve insulin sensitivity with subsequent amelioration of inhibitory effect of obesity and insulin resistance on the reproductive function and adjustment of the hyperandrogenic milieu.

[Mohamad F. Al-Sherbeny. **Targeting PCOS-associated Insulin Resistance: Aerobic Exercise and Hypocaloric Diet without Medications could adjust the Hyperandrogenic milieu and help Induction of Ovulation in Infertile PCOS women.** *Rep Opinion* 2015;7(1):34-40]. (ISSN: 1553-9873). <http://www.sciencepub.net/report>. 5

Keywords: PCOS, Dieting regimen, Exercise, Ovulation, Hyperandrogenemia

1. Introduction

Polycystic ovary syndrome is associated with a number of reproductive disorders and is characterized by the presence of polycystic ovaries, menstrual dysfunction, infertility or reduced fertility, and biochemical or clinical hyperandrogenism. PCOS also increases the prevalence and risk of a number of cardiometabolic disturbances including insulin resistance, hypertension, dyslipidemia, and diabetes (Jeanes et al., 2009).

In PCOS women, an impaired cardiopulmonary functional capacity strictly related to IR was documented. In women with proven coronary artery disease, an impaired cardiopulmonary functional capacity is associated with an increased risk of mortality for cardiovascular events (Kavanagh et al., 2003). Although nowadays PCOS women do not seem to be at increased risk for cardiovascular mortality (Wild et al., 2000) there are some intriguing reports showing higher CVR in PCOS even at an early age (Orio et al., 2004, Ehrmann, 2005).

Although the pathogenesis of PCOS is complex and not entirely understood, obesity (particularly

abdominal obesity) is mediated by the development of insulin resistance (Moran and Norman, 2004) and is closely linked to the development of this condition and its clinical features, particularly menstrual irregularities and increased serum androgens. The central role of insulin resistance in the manifestations of PCOS has led to it becoming a primary target for PCOS management (Norman et al., 2006).

Weight gain and obesity worsen the features of PCOS, while weight loss improves the features of PCOS. While there are potential barriers to successful weight management in young women who do not suffer from PCOS, women with PCOS may experience additional barriers. Weight management strategies in younger women with or without PCOS should encompass both the prevention of excess weight gain and achieving and maintaining a reduced weight through multidisciplinary lifestyle management, comprising dietary, exercise and behavioral therapy, as well as attention to psychosocial stress and practical and physiological barriers to weight management (Moran et al., 2010).

In non-PCOS subjects, lifestyle modification has proved as efficacious as pharmacological intervention in reducing the risk of developing type 2 diabetes mellitus. The National Institutes of Health clinical guidelines for the long-term treatment of overweight and obesity emphasize the importance of achievable and sustainable goals, notably a combination of diet modification, physical activity, and behavior therapy (McNaughton et al., 2009).

A separate line of evidence has shown that exercise training independent of weight loss in overweight and obese subjects with cardiometabolic disturbances and a wide range of insulin resistant states decreases abdominal fat and improves insulin sensitivity and an array of cardiovascular disease risk factors (Moro et al., 2009). Thus, the present study was designed to evaluate the impact of weight reduction and exercise interventions on the ovulatory function and hyperandrogenemic milieu of infertile PCOS women.

2. Patients and Methods

The present study was conducted at Department of Obstetrics and Gynecology, Benha University Hospital, since Jan 2009 till March 2010. After obtaining written fully informed patients' consents, the study included 90 PCOS diagnosed depending on the Rotterdam criteria (2004), in which at least two of the following three criteria were met: Oligomenorrhea (<8 spontaneous menstrual cycles/year for 3 years before enrollment) or amenorrhea, biochemical hyperandrogenemia (serum total testosterone level >0.8 ng/ml), and polycystic ovaries (>12 follicles in the 2–9 mm range and/or an ovarian volume >10 ml per ovary by transvaginal ultrasound TVU).

Patients with obesity inducing endocrinopathy, current or previous pregnancy within 1 year or the use of hormonal contraception within the last 6 months prior to inclusion in the study were excluded.

All patients underwent TVU examination and body height and weight measurements, and BMI was calculated as weight (kg)/height (m²), (Khosla and Lowe, 1967). Fat mass (FM), fat-free mass (FFM), and percent body fat (BF%) were determined by dual-energy x-ray absorptiometry. Obesity was graded after the WHO expert consultation (2004) as average (BMI <24.9), overweight (BMI 25–<30 kg/m²), obese (BMI ≥30–35 kg/m²) and morbid obese (BMI ≥35 kg/m²).

Fasting plasma and serum samples were collected and stored at -80°C for analysis after study completion. Testosterone and SHBG were measured by RIA using commercial enzymatic kits (Diagnostic Systems Laboratories). Free androgen index (FAI) was calculated as (testosterone/SHBG) x100. Plasma insulin concentrations were determined using a

commercial ELISA kit (Mercodia ELISA; ALPCO Diagnostics, Uppsala, Sweden) and insulin resistance was measured by homeostasis model assessment (HOMA). The HOMA-IR score was calculated as (fasting serum insulin (μU/ml) x [fasting plasma glucose (mg/ml)/18])/22.5 (Matthews et al., 1985) considering an abnormal HOMA-index >2 (Ascaso et al., 2001).

Enrolled women were randomly, irrespective of their clinical data, allocated into three groups according to 6-months lifestyle interventions without medications: diet only (Group A), diet and aerobic exercise (Group B) and diet and combined aerobic-resistance exercise (Group C). Body weight and BMI, HOMA-IR and FAI were evaluated at 3- and 6-months and were compared versus baseline measurements. For better outcome evaluation the extent of change was calculated as the 6-months value minus the baseline value and the percentage of BMI loss (%BMIL) was calculated as the difference between 6-month and baseline BMI divided by the baseline BMI multiplied by 100. Ovulation was monitored by measuring the serum concentration of progesterone on Day 21 of the menstrual cycle and serum progesterone level of ≥25 nmol/l was used to indicate ovulation that was assured using TVU for evident ovulation with a dominant follicle size >16 mm and the frequency of women got these follicles was considered as ovulation success rate.

Dieting and Exercise intervention

All subjects were prescribed the same energy-restricted, high-protein diet (5000–6000 kJ/d) for a planned weight loss of 10–15 kg over the study period. The diet provided 30% of energy as protein, 40% as carbohydrate, and 30% as fat. Group B women were assigned to undergo a walking/jogging program comprising five sessions per week. The training heart rate (HR) was based on a percentage of the maximum heart rate (MHR) achieved in the treadmill tests conducted at time of enrollment and at 3-m. Exercise intensity progressed from 30 min at 60–65% initial MHR to achieve 45 min at 75–80% MHR by study end. HR during exercise was monitored using a personal HR monitor (FS1 Polar Heart Rate Monitor; Polar Electro Oy, Kempele, Finland). Group C women performed the same aerobic exercise program as group B three times per week, and undertook a progressive resistance training program twice per week on non-consecutive days. The resistance training program consisted of five resistance exercises: bench press, lat pulldown, leg press, knee extension, and sit-ups. The training load was set using a percentage of 1RM, which was assessed for each exercise. For the first 2 wk, the training load was 50–60% 1RM and increased to 65–75% 1RM for the following weeks. The training

load was increased progressively once subjects could successfully perform three sets of 12 repetitions at that load.

Statistical analysis

Results were expressed as mean±SD, range, numbers and percentages. Intra-group data was statistically analyzed using paired t-test and inter-group analysis was examined using Wilcoxon Ranked test for related data (Z test). Statistical analysis was conducted using SPSS statistical program, (Version 10, 2002). P value <0.05 was considered statistically significant.

3. Results

Patients' characters evaluated prior to study enrollment showed non-significant difference among the three groups. The applied modalities of intervention significantly (p<0.05) reduced evaluated anthropometric measures at end of intervention period compared to baseline measures. The %BMIL was significantly higher in group B compared to groups A and C with significantly higher %BMIL reported in group C compared to group A (Table 1).

Table (1): Mean (±SD) BMI measures reported throughout the study period in studied groups compared to baseline measures

| | | Group A | Group B | Group C |
|--------------------------|----------|----------|-----------|----------|
| BW (kg) | Baseline | 101±10 | 104.8±9 | 103.9±9 |
| | 3-m | 95.3±9 | 96.7±9.2 | 95.8±5.3 |
| | 6-m | 91.7±9* | 90.5±8* | 92.6±7* |
| Body height (cm) | | 166.3±4 | 165.7±3 | 166.2±4 |
| BMI (kg/m ²) | Baseline | 36.8±3.8 | 38.4±3.1 | 37.6±2.9 |
| | 3-m | 34.9±3.5 | 35.4±3.5* | 34.6±3* |
| | 6-m | 33.6±4* | 33.2±3†* | 33.5±3* |
| | %BMIL | 8.75±1 | 13.6±4‡# | 10.9±3‡ |

BW: body weight
 BMI: body mass index
 %BMIL: percentage of BMI loss
 *: significant versus baseline
 †: significant versus 3-m
 ‡: significant versus group A
 #: significant versus group B

The %BF and WC showed significant progressive decrease with significant difference between %BF determined at 3-m and 6-m compared to baseline percentage with significant difference in favor of 6-m estimation. The extent of change of evaluated parameters was significantly higher in groups B and C compared to group A with non-significantly higher extent of change in group B compared to group C. Only the extent of decrease of FFM was significantly higher in group A compared to

groups B and C with non-significantly higher decrease of FFM in group C compared to group B, (Table 2 & 3).

Table (2): Mean (±SD) body fat measures reported throughout the study period in studied groups compared to baseline measures

| | | Group A | Group B | Group C |
|----------|----------|----------|-----------|------------|
| FM (kg) | Baseline | 48.1±4.1 | 46.4±4.6 | 47.7±7.2 |
| | 3-m | 45±5* | 42.6±5.7* | 43.1±6.7* |
| | 6-m | 43.2±3.8 | 38.2±5*† | 39.2±5*† |
| | EC | -4.9±4.1 | -8.2±4.8‡ | -8.5±6.3‡ |
| FFM (kg) | Baseline | 51.3±6.1 | 50.7±4.9 | 52.4±5.1 |
| | 3-m | 46±5.3* | 48.1±3.2* | 48.6±3.8* |
| | 6-m | 43.5±5* | 46.8±3.9* | 48.1±4.1* |
| | EC | -7.8±3.7 | -3.9±4.7‡ | -4.3±3.1‡ |
| BF% | Baseline | 47.1±5.1 | 46.9±3.2 | 48.1±4.1 |
| | 3-m | 46.8±6* | 44.1±4.1* | 46.4±3.6* |
| | 6-m | 45.9±6* | 42.3±3*† | 44.3±3.2*† |
| | EC | -1.2±4.5 | -4.6±3.9‡ | -3.8±2.8‡ |

FM: Fat mass
 FFM: fat-free mass
 BF%: body fat percentage
 *: significant versus baseline
 †: significant versus 3-m
 ‡: significant versus group A
 EC: Extent of change= 6-months level – baseline level

Table (3): Mean (±SD) WC (cm) measures reported throughout the study period in studied groups compared to baseline measures

| | Group A | Group B | Group C |
|------------------|------------|-------------|------------|
| Baseline | 105.9±10.9 | 106.3±11.2 | 104.7±12.1 |
| 3-m | 99.2±9.1* | 97.2±8.3* | 97.3±10.3* |
| 6-m | 93.5±8.4* | 90.7±10.2*† | 91.1±9.5*† |
| Extent of change | -11.4±9.65 | -15.6±10.7‡ | -13.6±11‡ |

*: significant versus baseline †: significant versus 3-m measures
 ‡: significant versus group A
 Extent of change= 6-months level – baseline level

Insulin resistance was modulated significantly using either of the applied strategies manifested as significant (p<0.05) reduction of FBG, FPI and HOMA-IR at the end of intervention period compared to baseline levels. Group A patients showed the least extent of HOMA-IR change that was significantly inferior to that reported in groups B and C with non-significantly lower HOMA-IR in group C compared to group B.

Prior to starting interventions, 63 women were insulin resistant with IR>2, while 27 women had IR<2 with non-significant difference between the three

groups as regards distribution of insulin resistant women. At end of interventions, only 15 women were still insulin resistant (IR>2) with successful IR reduction rate of 79.4%. All intervention modalities significantly decreased the frequency of patients had IR compared to pre-treatment frequency and with higher frequency of insulin sensitivity in groups B and C compared to group A, but with non-significant difference between groups B and C, despite being in favor of group B, (Table 4).

Mean baseline levels of androgenic hormones showed non-significant (p>0.05) difference between studied patients. Three months of intervention induced non-significant (p>0.05) changes of androgenic hormones serum levels compared to their baseline levels with non-significant difference among groups despite being least in group A. On contrary, serum levels estimated at 6-m of intervention showed significant difference compared to their baseline levels in groups B and C, but the difference was non-significant in group A.

For better result adjustment, results were evaluated as the mean extent of change; the extent of decreased serum testosterone levels was non-significant (p>0.05) among studied groups despite being least in group A, while the extent of increased serum SHGB was significantly (p<0.05) higher in groups B and C compared to group A and was in favor of group B.

Table (4): Patients' insulin resistance data recorded at end of 6-months intervention period compared versus data obtained at time of study enrollment

| | | Group A | Group B | Group C |
|---------------------|----------|------------|-------------|-------------|
| FBG | Baseline | 124.7±10.7 | 127.1±9.1 | 126.3±11.4 |
| | 6-m | 118.3±7.6* | 121.9±6.8* | 122±8.7* |
| FPI | Baseline | 5.3±1.25 | 5.7±1 | 5.4±1.2 |
| | 6-m | 4.51±1.31* | 4.23±1.19* | 4.46±1.15* |
| HOMA-IR | Baseline | 1.7±0.48 | 1.87±0.3 | 1.8±0.3 |
| | 6-m | 1.42±0.32* | 1.22±0.26*‡ | 1.23±0.22*‡ |
| % of HOMA-IR change | | 0.29±0.13 | -0.65±0.18‡ | -0.57±0.14‡ |
| IR:IS ratio | Baseline | 16:14 | 18:12 | 19:11 |
| | 6-m | 8:22 | 2:28‡ | 3:27‡ |

FBG: fasting blood glucose
 FPI: fasting plasma insulin
 IR: insulin resistant
 IS: insulin sensitive
 *: significant versus baseline ‡: significant versus group A

As regards FAI, all modalities of intervention showed progressive decrease of FAI that was significant at 6-m compared to baseline in the three studied groups. The extent of FAI decrease in group B was significant (p<0.05) compared to group A, but non-significant (p>0.05) compared to group C with non-significant (p>0.05) difference in favor of group C compared to group A, (Table 5, Figure 1).

Table (5): Mean (±SD) levels of androgenic hormones estimated in the studied groups

| | | Group A | Group B | Group C |
|---------------|------|-----------|-----------|------------|
| Test (nmol/l) | Base | 2.33±0.6 | 2.41±0.6 | 2.49±0.5 |
| | 3-m | 2.12±0.6 | 2.22±0.5 | 2.3±0.54 |
| | 6-m | 2.1±0.6 | 2±0.54* | 2±0.56* |
| | EC | 0.29±0.1 | 0.4±0.09 | 0.37±0.1 |
| SHGB (nmol/l) | Base | 27.4±9.1 | 33.6±11.2 | 29.5±10.1 |
| | 3-m | 30.6±10.2 | 39.4±13.2 | 34±11.67 |
| | 6-m | 31.5±10.5 | 47±15.7* | 40±13.7* |
| | EC | 4.1±1.37 | 13.4±4.5† | 10.3±3.55† |
| FAI | Base | 46.6±4.24 | 47±4.26 | 47.3±4.23 |
| | 3-m | 45.3±4.3 | 43.6±4.5 | 45.2±4 |
| | 6-m | 43.9±4.5* | 42.3±4.5* | 44.2±4.1* |
| | EC | 2.69±1.3 | 4.7±2.4† | 3.15±1.1 |

Base: baseline measure
 SHBG: sex hormone binding globulin
 FAI: free androgen index
 *: significant versus baseline
 †: significant versus group A
 EC: Extent of change= 6-months level – baseline level




Figure 1: Mean extent of change of serum androgenic hormones and FAI




Figure 2. Patients' distribution according to successful ovulation

Fifty-nine women got ovulation throughout the intervention period with ovulatory success rate of 65.6%. Ovulatory success rate in group A 56.7%, 73.3% in group B and was 66.7% in group C with non-significant difference among studied groups despite being in favor of group B, (Figure 2).

4. Discussion

Through the present study, the applied models of intervention significantly reduced the evaluated anthropometric measures with significantly higher extent of change in groups B and C compared to group A. These data point to the complementary role between dieting regimens and exercise to affect whole body fat and was in line with the observation of both Ormsbee et al (2009) who found the effects of exercise per se on visceral adipose tissue depot are relatively limited compared with the major effects of hypocaloric diet alone and are closely associated with changes in total fat mass and Christiansen et al (2009) who reported that the mechanism behind resistance exercise contributing to improved body composition may in part be due to enhanced subcutaneous abdominal adipose tissue lipolysis and improved whole body energy expenditure and fat oxidation.

However, FFM was significantly higher in group A compared to groups B and C with non-significantly higher decrease of FFM in group C compared to group B. These findings illustrate the beneficial effect of chronic weight reduction programs and exercise intervention on body constitutional parameters and fat content. However, it was evident that exercise induced more stored fat loss with preservation or minimal affection of fat free mass which was more affected by simple weight reduction program leading to muscle wasting, but extensive resistance exercise also induced more FFM loss compared to aerobic exercise without resistance training. These findings go in hand with Chomentowski et al (2009) who found diet-induced

weight loss significantly decreased muscle mass; however, the addition of moderate aerobic exercise to intentional weight loss attenuated the loss of muscle mass.

Insulin resistance was modulated significantly using either of the applied strategies manifested as significant reduction of FBG, FPI and HOMA-IR at the end of intervention period despite the more superior effect of combined dieting and exercise compared to dieting alone. In line with the obtained regulations, at the end of interventions, only 15 women were still IR with successful IR reduction rate of 79.4%. Thus, either dieting regimen alone or combined with exercise induced improved insulin sensitivity with subsequent proper utilization of blood glucose so reducing their blood levels, a finding coincided with Straznicky et al (2009) who found weight loss reverses blunted sympathetic responsiveness to glucose ingestion in insulin-resistant subjects with metabolic syndrome, which is relevant to postprandial energy utilization and body weight homeostasis.

In support of the beneficial effects imposed by exercise on blood glucose regulation, Clough et al (2009) found decreased insulin-mediated glucose uptake in skeletal muscle is associated with impaired muscle microvascular exchange capacity that was negatively associated with a measure of glycemia and positively associated with insulin sensitivity, independently of visceral fat mass and could be improved by muscular exercise not by simple or drug induced lowering of blood lipid content. Such findings could be attributed to the facts that insulin is a regulator of muscle proteins and can stimulate the synthesis of mitochondrial proteins and IR influence the mitochondrial function and to the improved cardiopulmonary functions, which proved to be affected by IR, with chronic exercise (Orio et al., 2006). The impact of exercise on autonomic nervous system could be another explanation for the better control of exercise on PCOS associated metabolic disturbances and its sequale. In support of such attribution, Giallauria et al (2008) found exercise training improves autonomic function and inflammatory pattern in PCOS women and Stener-Victorin et al (2004) demonstrated that low-frequency electroacupuncture and physical exercise lowers high sympathetic nerve activity in women with PCOS with its subsequent hyperglycemia and cardiopulmonary effects.

Despite the non-significant differences reported between groups B and C concerning anthropometric measures and HOMA-IR score and components, these difference illustrate the impact of training characters on these parameters, this assumption support that previously reported by Bajpeyi et al. (2009) who

found that in overweight/obese subjects a relatively chronic persistence of enhanced insulin action may be obtained with endurance-oriented exercise training; this persistence, however, is dependent on the characteristics of the exercise training performed.

The applied models of interventions significantly improved the hyperandrogenemic milieu in the studied PCOS women with ovulation induction success rate of 65.6% without use of medications. These findings were in line with that previously and recently observed in literature; Moran et al (2009) reported that the emerging evidence suggests that exercise offers additional benefits to dietary energy restriction for reproductive features of PCOS and should be used as the primary therapy in overweight and obese women with PCOS for treatment of metabolic complications and improved ovulatory function and pregnancy.

Thomson et al (2010) reported significant reductions in waist circumference, blood pressure, fasting insulin, fasting glucose, homeostasis model assessment of insulin resistance, testosterone, free androgen index, and an increase in SHBG with improved heart rate recovery which suggests improved autonomic function and thus highlights the importance of weight loss and exercise to reduce the cardiovascular disease risk in PCOS women.

Vause et al (2010) defined the guidelines for management of PCOS as following: weight loss, exercise, and lifestyle modifications have been proven effective in restoring ovulatory cycles and achieving pregnancy in overweight women with PCOS and should be the first-line option for these women.

In support of the applied intervention model without medications, Karimzadah and Javedani (2010) reported that lifestyle modification of PCOS women achieved a significant reduction in waist circumference, total androgen, and lipid profile with clinical pregnancy rate of 20% with lifestyle modification compared to 12.2% in those received clomiphene citrate alone, 14.4% with metformin alone, 14.8% with combined clomiphene citrate and metformin.

It could be concluded that in PCOS women combined weight reduction regimens associated with aerobic physical exercise intervention induce weight loss and improves insulin sensitivity with subsequent amelioration of inhibitory effect of obesity and insulin resistance on the reproductive function and adjustment of the hyperandrogenic milieu.

Acknowledgements:

Author is grateful to Faculty of Medicine, Benha University for financial support to carry out this work. Also, thanks Dr. Adel F. Al-Kholy for conducting the laboratory measures at Endocrinology Lab Unit,

Medical Biochemistry Department, Benha Faculty of Medicine.

Corresponding Author:

Dr. Mohamad F. Al-Sherbeny
Department of Obstetrics & Gynecology
Faculty of Medicine, Benha University
Benha, Kaluobia, Egypt
E-mail: Mahfarag61@yahoo.com

References

1. Jeanes YM, Barr S, Smith K, Hart KH. Dietary management of women with polycystic ovary syndrome in the United Kingdom: the role of dietitians. *J Hum Nutr Diet.* 2009; 22(6):551-8.
2. Kavanagh T, Mertens DJ, Hamm LF, Beyene J, Kennedy J, Corey P, Shephard RJ. Peak oxygen intake and cardiac mortality in women referred for cardiac rehabilitation. *J Am Coll Cardiol.* 2003; 42:2139-43.
3. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. *Clin Endocrinol (Oxf).* 2000; 52:595-600.
4. Orio Jr F, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G, Colao A. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case control study. *J Clin Endocrinol Metab.* 2004; 89:3696-701.
5. Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med.* 2005; 352:1223-36.
6. Moran L and Norman RJ: Understanding and managing disturbances in insulin metabolism and body weight in women with polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol.* 2004; 18(5):719-36.
7. Norman RJ, Homan G, Moran L, Noakes M. Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome. *Endocrine.* 2006; 30(1):35-43.
8. Moran LJ, Lombard CB, Lim S, Noakes M, Teede HJ. Polycystic ovary syndrome and weight management. *Women's Health (Lond Engl).* 2010; 6(2):271-83.
9. McNaughton SA, Dunstan DW, Ball K, Shaw J, Crawford D. Dietary quality is associated with diabetes and cardio-metabolic risk factors. *J Nutr.* 2009; 139(4):734-42.
10. Moro C, Pasarica M, Elkind-Hirsch K, Redman LM. Aerobic exercise training improves atrial natriuretic peptide and catecholamine-mediated lipolysis in obese women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2009; 94(7):2579-86.

11. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril.*, 2004; 81:19–25.
12. Khosla T and Lowe CR. Indices of obesity derived from body weight and height. *Br J Prev Soc Med.*, 21: 121-8, 1967.
13. WHO expert consultation. Appropriate Body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet*, 2004; 157-63.
14. Matthews DR, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*, 1985; 28:412–9.
15. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. *Med Clin (Barc)*, 2001; 117: 530–3.
16. Ormsbee MJ, Choi MD, Medlin JK, Geyer GH, Trantham LH, Dubis GS, Hickner RC. Regulation of fat metabolism during resistance exercise in sedentary lean and obese men. *J Appl Physiol.* 2009; 106(5):1529-37.
17. Christiansen T, Paulsen SK, Bruun JM, Overgaard K, Ringgaard S, Pedersen SB, Positano V, Richelsen B. Comparable reduction of the visceral adipose tissue depot after a diet-induced weight loss with or without aerobic exercise in obese subjects: a 12-week randomized intervention study. *Eur J Endocrinol.* 2009; 160(5):759-67.
18. Chomentowski P, Dub JJ, Amati F, Stefanovic-Racic M, Zhu S, Toledo FG, Goodpaster BH. Moderate exercise attenuates the loss of skeletal muscle mass that occurs with intentional caloric restriction-induced weight loss in older, overweight to obese adults. *J Gerontol A Biol Sci Med Sci.* 2009; 64(5):575-80.
19. Straznicky NE, Lambert GW, McGrane MT, Masuo K, Dawood T, Nestel PJ, Eikelis N, Schlaich MP, Esler MD, Socratous F, Chopra R, Lambert EA. Weight loss may reverse blunted sympathetic neural responsiveness to glucose ingestion in obese subjects with metabolic syndrome. *Diabetes.* 2009; 58(5):1126-32.
20. Clough GF, Turzyniecka M, Walter L, Krentz AJ, Wild SH, Chipperfield AJ, Gamble J, Byrne CD. Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatment. *Diabetes*, 2009; 58(5):1185-91.
21. Orio F Jr, Giallauria F, Palomba S, Cascella T, Manguso F, Vuolo L, Russo T, Tolino A, Lombardi G, Colao A, Vigorito C. Cardiopulmonary impairment in young women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2006; 91(8):2967-71.
22. Giallauria F, Palomba S, Maresca L, Vuolo L, Tafuri D, Lombardi G, Colao A, Vigorito C, Francesco O. Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). *Clin Endocrinol (Oxf)*. 2008; 69(5):792-8.
23. Stener-Victorin E, Jedel E, Janson PO, Sverrisdottir YB. Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. *Am J Physiol Regul Integr Comp Physiol.* 2009;297(2):R387-95.
24. Bajpeyi S, Tanner CJ, Slentz CA, Duscha BD, McCartney JS, Hickner RC, Kraus WE, Houmard JA. Effect of exercise intensity and volume on persistence of insulin sensitivity during training cessation. *J Appl Physiol.* 2009; 106(4):1079-85.
25. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. *Fertil Steril.* 2009; 92(6):1966-82.
26. Thomson RL, Buckley JD, Noakes M, Clifton PM, Norman RJ, Brinkworth GD. Heart rate recovery improves after weight loss in overweight and obese women with polycystic ovary syndrome. *Fertil Steril.* 2010;93(4):1173-8.
27. Vause TD, Cheung AP, Sierra S, Claman P, Graham J, Guillemin JA, Lapens L, Steward S, Wong BC. Ovulation induction in polycystic ovary syndrome. *J Obstet Gynaecol Can.* 2010; 32:495-502.
28. Karimzadeh MA and Javedani M. An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. *Fertil Steril.* 2010; 94(1):216-20.